AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Photocure ASA

Report Publication Announcement Oct 25, 2022

3714_rns_2022-10-25_21051f33-f39b-48a2-863c-e4b44b20812f.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Photocure ASA: Invitation to presentation of third quarter 2022 financial results

Photocure ASA: Invitation to presentation of third quarter 2022 financial results

Oslo, Norway, 25 October 2022: Photocure ASA (Photocure, PHO: OSE) will announce

the third quarter 2022 financial results on Wednesday 2 November 2022 at 08:00

CEST and will present a live webcast at 14:00 CEST the same day.

The quarterly report and presentation will be published at 08:00 CEST and will

be publicly available at www.photocure.com.

The investor presentation will be streamed live and be hosted by Daniel

Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and

questions can be submitted throughout the event. The presentation is scheduled

to conclude at 14:45 CEST.

The streaming event is available through

https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20221102_7.

For further information, please contact:

Photocure

Erik Dahl

CFO

Tel: +47 45055000

Email: [email protected]

Media and IR enquiries:

Geir Bjørlo

Corporate Communications (Norway) Tel: +47 91540000

Email: [email protected]

About Photocure

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, making

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

www.photocure.com, www.hexvix.com, www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

Talk to a Data Expert

Have a question? We'll get back to you promptly.